Amazing! MedComm Included in the ESCI Database in Just a Year!
Open the phone and scan
In just one year, MedComm was successfully included in the ESCI database, and articles published online by the journal will be included in real-time by Web of Science, marking another milestone in the development of the journal.
The ESCI (Emerging Sources Citation Index) database is a high-quality journal index selected according to Thomson Reuters Journal Selection Criteria. It mainly includes outstanding academic journals with important influence in emerging research fields, and forms the core collection of Web of Science together with SCI, SSCI and AHCI. For all journals included in the ESCI database, their articles can be retrieved on the SCI website to facilitate the understanding of the latest scientific research and discoveries. Most of the journals included in ESCI are officially included as SCI journals in a short period of time, and joining ESCI has become an important ticket for journals to be selected by SCI.
MedComm is another excellent biomedical journal created by Professor Wei Yuquan, an academician of the Chinese Academy of Sciences. The Signal Transduction and Targeted Therapy (STTT), a first-class academic journal founded by Professor Wei Yuquanin 2016, had an impact factor of 18.187 in 2020. It is located in the Q1 area of the JCR section—a SCI journal, and ranks No. 5 in the global biochemistry and molecular biology journals and No.11 in cell biology journals. We have reason to believe that MedComm has unlimited potential and can be expected to become a high-level international journal in the future.
MedComm is a biomedical English journal published by the world's top publishing group Wiley in 2020 (https://onlinelibrary.wiley.com/journal/26882663). It has been included in well-known databases such as ESCI, DOAJ, BIOSIS Previews, etc. Most of its papers are also included by PubMed. MedComm cordially invites all science researchers, doctors and postgraduates in the field of biomedicine to submit manuscripts.
Its editorial board is led by Prof. James Henderson Naismith of University of Oxford (a fellow of the Royal Society (UK) and the Royal Society of Edinburgh) , Prof. Günter P. Wagner of Yale University (a member of the American National Academy of Sciences, the American Association for the Advancement of Science, and the American Academy of Arts and Sciences), and Prof. Wei Yuquan of the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University (an academician of the Chinese Academy of Sciences). Members of the editorial board comprise eminent scientists from more than 10 countries in the world, of which more than 20% are domestic and foreign academicians, and more than 60% are foreign experts, including Academician Song Weihong, Academician Jiang Hualiang, Professor Peng Yong, Professor Huang Canhua, Professor He Mingliang and other famous experts and professors.
Since its inception, MedComm has always adhered to a high-level, international, and high-standard strategy for running a journal. All published content has undergone strict peer review. With professional and efficient editorial team management, it has been widely recognized by peer scholars at home and abroad. MedComm receives high-level manuscripts from top universities and research institutions around the world. More than 80 papers have been published online, including the articles written by Academician Kam. W. Leong, Editor-in-Chief of Biomaterials, Academician Song Weihong from the University of British Columbia, Professor Gary A. Piazza from the University of South Alabama, Professor Masoud Mozafari from the University of Toronto, Professor Wenjun Deng from Harvard Medical School, Professor Chen Zhesheng from St. John's University, Yao Zhi from Tianjin Medical University, Ye Lilin from the Third Military Medical University, Wang Fudi from Zhejiang University and many other academicians and professors at home and abroad. MedComm sincerely thanks the authors, reviewers, editors and readers for their great contributions. MedComm will continue to work hard to publish more high-quality papers and better serve readers and authors around the world.